Ainos, Inc.

NasdaqCM:AIMD Stock Report

Market Cap: US$10.6m

Ainos Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Chun-Hsien Tsai

Chief executive officer

US$916.0k

Total compensation

CEO salary percentage20.31%
CEO tenure5.4yrs
CEO ownership5.6%
Management average tenureno data
Board average tenure5.4yrs

Recent management updates

Recent updates

Analysis Article • Dec 12

Ainos (NASDAQ:AIMD) Has Debt But No Earnings; Should You Worry?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article • Aug 29

Ainos (NASDAQ:AIMD) Is Carrying A Fair Bit Of Debt

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Mar 10

We Think Ainos (NASDAQ:AIMD) Has A Fair Chunk Of Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article • Aug 28

Here's Why Ainos (NASDAQ:AIMD) Can Afford Some Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article • May 15

Here's Why Ainos (NASDAQ:AIMD) Can Afford Some Debt

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Seeking Alpha • Sep 30

Ainos rises 50% on positive data from animal study trial of Veldona to treat COVID-19

Ainos (NASDAQ:AIMD) has surged 50% premarket after the company said its low-dose oral interferon (IFN)-alpha formulation Veldona showed a positive effect on lungs infected with the the Omicron variant of the coronavirus by regulating the immune response, thereby expediting recovery of hamsters. The copany had filed an application to the U.S. Food and Drug Administration (FDA) seeking clearance to conduct a phase 2 trial for the drug. The study tested the effectiveness of Veldona over a sixteen-day course and compared with hamsters in the placebo group. The hamsters in the group receiving Veldona showed resistance to body weight loss immediately after infection, then showed a better recovery trend in the following three days.
Seeking Alpha • Aug 24

Ainos stock rises on FDA filing for starting phase 2 trial of Veldona for COVID-19

Ainos (NASDAQ:AIMD) filed an application to the U.S. Food and Drug Administration (FDA) seeking clearance to conduct a phase 2 trial of its low-dose oral interferon (IFN)-alpha formulation Veldona to treat mild symptoms related to COVID-19. Earlier in August, the company said that it had started a phase 2 trial of Veldona in patients with mild COVID-19 in Taiwan, following results from preclinical studies. "Our Company is investigating whether impaired type I IFN could be related to persistent high blood viral loads and inflammatory responses in COVID-19 cases," said Chairman President and CEO Chun-Hsien Tsai. AIMD +5.28% to $2.59 premarket Aug. 24
Seeking Alpha • Aug 15

Amarillo Biosciences GAAP EPS of -$0.01, revenue of $636.62M

Amarillo Biosciences press release (NASDAQ:AIMD): Q2 GAAP EPS of -$0.01. Revenue of $636.62M (+213.6% Y/Y).

CEO Compensation Analysis

How has Chun-Hsien Tsai's remuneration changed compared to Ainos's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2026n/an/a

-US$14m

Mar 31 2026n/an/a

-US$14m

Dec 31 2025US$916kUS$186k

-US$15m

Sep 30 2025n/an/a

-US$15m

Jun 30 2025n/an/a

-US$16m

Mar 31 2025n/an/a

-US$15m

Dec 31 2024US$302kUS$123k

-US$15m

Sep 30 2024n/an/a

-US$16m

Jun 30 2024n/an/a

-US$15m

Mar 31 2024n/an/a

-US$15m

Dec 31 2023US$1mUS$96k

-US$14m

Sep 30 2023n/an/a

-US$10m

Jun 30 2023n/an/a

-US$15m

Mar 31 2023n/an/a

-US$14m

Dec 31 2022US$4mUS$100k

-US$14m

Sep 30 2022n/an/a

-US$13m

Jun 30 2022n/an/a

-US$7m

Mar 31 2022n/an/a

-US$5m

Dec 31 2021US$82kUS$45k

-US$4m

Compensation vs Market: Chun-Hsien's total compensation ($USD916.01K) is above average for companies of similar size in the US market ($USD651.74K).

Compensation vs Earnings: Chun-Hsien's compensation has increased whilst the company is unprofitable.

CEO

Chun-Hsien Tsai (56 yo)

5.4yrs
Tenure
US$916,008
Compensation

Mr. Chun-Hsien Tsai has been Chairman of Board, President and Chief Executive Officer at Ainos, Inc. since April 15, 2021 and served as its Chief Financial Officer since April 15, 2021 until August 11, 202...

Board Members

NamePositionTenureCompensationOwnership
Chun-Hsien Tsai
CEO, President & Chairman of the Board5.4yrsUS$916.01k5.56%
$ 590.9k
Yao-Chung Chiang
Independent Director5.4yrsUS$194.80k0.15%
$ 16.2k
Pao-Sheng Wei
Independent Director4.3yrsUS$200.80k1.23%
$ 130.9k
Wen-Han Chang
Independent Director5.4yrsUS$199.30k1.38%
$ 146.2k
Ting-Chuan Lee
Director5.4yrsUS$699.03k10.93%
$ 1.2m
Chun-Jung Tsai
Director5.4yrsUS$699.03k8.91%
$ 947.8k
Chung-Yi Tsai
Director5.4yrsUS$190.80k1.23%
$ 130.9k
5.4yrs
Average Tenure
56yo
Average Age

Experienced Board: AIMD's board of directors are considered experienced (5.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/13 14:49
End of Day Share Price 2026/09/11 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ainos, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.